EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings.
T.D. Cowen 45th Annual Health Care Conference (March 3-5, 2025) | |
Format: Date: Time: | Corporate presentation Monday, March 3, 2025 11:10AM ET |
Location: Link: | Boston, MA /webcast/cowen177/register.aspx?conf=cowen177&page=xoma&url=https://wsw.com/webcast/cowen177/xoma/2033463 |
Leerink 2025 Global Healthcare Conference (March 9-12, 2025) | |
Format: | Fireside chat |
Date: | Monday, March 10, 2025 |
Time: | 2:20PM ET |
Location: Link: | Miami Beach, FL /webcast/leerink38/register.aspx?conf=leerink38&page=xoma&url=https://wsw.com/webcast/leerink38/xoma/2233817 |
XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of each presentation will be available and archived on the site for 90 days after the event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
XOMA Investor Contact | XOMA Media Contact |
Juliane Snowden | Kathy Vincent |
XOMA Royalty | KV Consulting & Management |
+1 646-438-9754 | +1 310-403-8951 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$26.17 |
Daily Change: | -0.79 -2.93 |
Daily Volume: | 65,367 |
Market Cap: | US$308.280M |
May 13, 2025 May 07, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load